IP Library Granted Patent US 11,628,186
Granted Patent B2
US 11,628,186 · App. 16/974,068 · Granted Apr 18, 2023

Method and composition for the reduction of viral replication, duration and spread of the COVID-19 and the flu

Inventor: Alain Martin (Flemington, NJ)
Assignee: CELLULAR SCIENCES, INC.
A61K33/42A61K9/0073A61K9/0078A61K9/08A61K31/19A61K33/06A61P11/00A61P11/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,628,186
App. No.
16/974,068
Granted
Apr 18, 2023
Kind
B2
Abstract

A method for stimulating the synthesis of nasal nitric oxide and nasal and lung surfactants to inhibit the docking and adhesion of viruses to cellular receptors, including ACE2, to reduce viral replication, duration, spread and severity of infections, and also to inhibit lung fibrosis, increase the synthesis of serotonin to reduce coughing and mouth breathing, reduce the cytokine storm produced by LI-6 caused by viruses such as COVID-19 and flu in patients susceptible to these infections, including patients with hypoxemia, asthma, chronic obstructive pulmonary disease, cystic fibrosis, diabetics, interstitial lung disease, pulmonary fibrosis, allergic rhinitis, sinusitis, smokers, sleep apnea and lung cancer, which includes: contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents: sodium pyruvate; a phosphate; a salt of calcium; and a salt of magnesium.

Claims (20)

1. Method for reducing duration, spread and severity of infections caused by coronaviruses in patients susceptible to these infections, which comprises:

contacting mammalian cells with a therapeutically effective amount of a composition, said composition including the following constituents:

a) a saline liquid carrier;

b) sodium pyruvate;

c) a phosphate selected from the group consisting of a calcium phosphate, a potassium phosphate, magnesium phosphate, and zinc phosphate and combinations thereof;

d) a salt of calcium is selected from the group consisting of calcium chloride, calcium carbonate, calcium acetate, calcium citrate, calcium lactate, calcium sulfate, and combinations thereof; and

e) a salt of magnesium is selected from the group consisting of magnesium chloride, magnesium phosphate, magnesium sulfate, magnesium bicarbonate, and combinations thereof

wherein a dosage of said pyruvate salt ranges from about 0.0001 mg to about 1 gram; and

wherein the combined dosage of said phosphate, said salt of calcium and said salt of magnesium ranges from about 0.0001 mg to about 1 gram.

2. The method of claim 1 wherein said phosphate is a calcium phosphate selected from the group consisting of calcium phosphate, di-calcium phosphate and combinations thereof.

3. The method of claim 1 wherein said phosphate is a potassium phosphate selected from the group consisting of potassium phosphate, di-potassium phosphate, tri-potassium phosphate, and combinations thereof.

4. The method of claim 1 wherein said composition is a saline solution consisting of sodium chloride, sodium pyruvate, calcium chloride, potassium phosphate and magnesium chloride.

5. The method of claim 1 wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01 mg to about 1 gram.

6. The method of claim 1 wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01 mg to about 1 gram; and ranges from 0.001 mg to about 1 gram for the combination of the following constituents: phosphate, salt of calcium and salt of magnesium.

7. The method of claim 1 wherein said coronaviruses are selected from the group consisting of COVID-19 and influenza.

8. The method of claim 7 wherein said phosphate is a calcium phosphate selected from the group consisting of calcium phosphate, di-calcium phosphate and combinations thereof.

9. The method of claim 7 wherein said phosphate is a potassium phosphate selected from the group consisting of potassium phosphate, di-potassium phosphate, tri-potassium phosphate, and combinations thereof.

10. The method of claim 7 wherein said composition is a saline solution consisting of sodium chloride, sodium pyruvate, calcium chloride, potassium phosphate and magnesium chloride.

11. The method of claim 7 wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01 mg to about 1 gram.

12. The method of claim 7 wherein said composition contains the following amounts of said constituents: sodium pyruvate ranges from about 0.01 mg to about 1 gram; and ranges from 0.001 mg to about 1 gram for the combination of the following constituents: phosphate, salt of calcium and salt of magnesium.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2020
From: MARTIN, ALAIN DR.
To: CELLULAR SCIENCES, INC
Reel/Frame 054588/0951 →
Continuity (3)
Continuation 16873379 · Apr 1, 2020
Continuation In Part 15441552 · Feb 24, 2017
Related Publication 20210008105A1 · Jan 14, 2021
Cited By (1)
US 12,611,389